Tunable Human ECM Platform Technology

One platform engine enables multiple biomedical applications

Founded by biomaterials veterans with 74+ combined patents, we've developed the first tunable hybrid biomaterial system using human collagen that enables what synthetic materials cannot achieve

Our technology creates tunable hybrid biomaterials using human collagen from cultured fibroblasts. This breakthrough technology - protected by US Provisional patents - represents one of the first applications using human collagen to create materials with precisely adjustable properties.

The platform combines human atelopeptide collagen with advanced polymer systems to create hybrid biomaterials with tunable rheological properties, enhanced thermal stability, and superior biocompatibility. This enables functionalization with other human ECM proteins from the same core process, plus integration of biological actives including antibodies, growth factors, and cytokines.

Platform Advantages: Every application - from neural interfaces to space medicine - builds on the same validated technology foundation, accelerating development while reducing regulatory and financial risk.

The Ambient Biostasis device, BMI technology, prostate spacer gel, and cell therapy delivery vehicle all share this core platform, enabling rapid development of new products with reduced costs.

How Do We Manufacture Human ECM

Scalable Human Collagen Manufacturing from Cells

We can produce high-purity, biocompatible human collagen, a critical component in all our medical devices. By utilizing engineered fibroblast cells, we generate extracellular matrix (ECM) proteins that enhance the functionality and compatibility of our products. This advanced technology allows us to create versatile medical solutions that address a wide range of biomedical needs.

Brain-Machine Interface (BMI)

Our cutting-edge Brain-Machine Interface (BMI) technology represents the next frontier in medical innovation. Utilizing our human collagen platform, this device enhances neural interfaces, enabling groundbreaking applications in neurology and prosthetics. Our BMI technology aims to improve tissue integration, reduce immune response, and offer long-lasting solutions for patients with complex medical needs.

Our neural interfaces leverage the platform's unique thermal stability and biocompatibility. Unlike synthetic polyimides, our tunable human ECM materials truly integrate with neural tissue, enabling long-term stability impossible with conventional approaches.

Platform Validation: Prostate Cancer Hydrogel Spacer

An essential step in Trylle Biologics’ product roadmap, the Prostate Cancer Hydrogel Spacer will be a 510(k)-cleared device designed to reduce radiation exposure to surrounding healthy tissues during prostate cancer treatment. This product strategically positions Trylle’s Human Collagen Biomaterials for FDA clearance, as it requires only animal studies rather than human clinical trials, expediting regulatory approval.

This represents our platform's entry into clinical markets, validating our tunable hydrogel technology through FDA 510(k) pathway while establishing GMP manufacturing capabilities that support all future applications

The injectable spacer leverages Trylle’s Human Collagen Biomaterials to provide a high level of biocompatibility, offering a non-inflammatory, natural-tissue-like medium for safe, effective use in radiation therapy. This streamlined approval pathway for the hydrogel spacer serves as an entry point for Trylle to validate the safety, efficacy, and manufacturing capabilities of its products with the FDA. Success with this initial product will establish regulatory momentum and credibility, setting the stage for more complex applications such as BCIs.

By introducing the hydrogel spacer, Trylle can establish a scalable, FDA-compliant manufacturing process for its collagen biomaterials, positioning the company for expedited entry into the BCI and broader medtech markets. This proactive strategy underscores Trylle’s commitment to innovation, safety, and regulatory rigor as it pioneers the next wave of neural and medtech solutions.

At Trylle Biologics, we are not just creating products; we are shaping the future of healthcare. Our commitment to innovation, quality, and patient care drives everything we do. Whether you are a healthcare provider, investor, or partner, we invite you to join us on this exciting journey toward a healthier, more connected world.

For more information about our products, services, or investment opportunities, please reach out to us at info@trylleinc.com.